The US medical devices industry saw a drop of 26.8% in overall deal activity during September 2020, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 60 deals worth $10.18bn were announced in September 2020, compared to the 12-month average of 82 deals.
Venture financing was the leading category in the month in terms of volume with 35 deals which accounted for 58.3% of all deals.
In second place was M&A with 18 deals, followed by private equity with seven transactions, respectively accounting for 30% and 11.7% of overall deal activity in the country’s medical devices industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $9.35bn, while venture financing and private equity deals totalled $419.95m and $410m, respectively.
US medical devices industry deals in September 2020: Top deals
The top five medical devices industry deals accounted for 94.02% of the overall value during September 2020.
The combined value of the top five medical devices deals stood at $9.57bn, against the overall value of $10.18bn recorded for the month.
The top five medical devices industry deals of September 2020 tracked by GlobalData were:
1) Illumina’s $8bn acquisition of Grail
2) The $780m acquisition of Advanced Instruments by Patricia Industries
3) ArchiMed’s $350m private equity deal with North American Science Associates
4) The $240m asset transaction with Integra LifeSciences by Smith & Nephew
5) CryoLife’s acquisition of Ascyrus Medical for $200m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.